CDC Model Performance Evaluation Program (MPEP) for Mycobacterium tuberculosis and Nontuberculous Mycobacteria Drug Susceptibility Testing

ICR 201311-0920-007

OMB: 0920-0600

Federal Form Document

Forms and Documents
Document
Name
Status
Form and Instruction
Modified
Form and Instruction
Modified
Form and Instruction
Modified
Justification for No Material/Nonsubstantive Change
2013-11-07
Supplementary Document
2013-11-07
Supplementary Document
2013-04-22
Supplementary Document
2013-04-22
Supplementary Document
2013-04-22
Supplementary Document
2013-04-22
Supplementary Document
2013-04-22
Supplementary Document
2013-04-22
Supporting Statement A
2013-11-07
ICR Details
0920-0600 201311-0920-007
Historical Active 201304-0920-020
HHS/CDC 20828
CDC Model Performance Evaluation Program (MPEP) for Mycobacterium tuberculosis and Nontuberculous Mycobacteria Drug Susceptibility Testing
No material or nonsubstantive change to a currently approved collection   No
Regular
Approved without change 11/14/2013
Retrieve Notice of Action (NOA) 11/12/2013
  Inventory as of this Action Requested Previously Approved
05/31/2016 05/31/2016 05/31/2016
558 0 558
156 0 156
0 0 0

As part of the continuing effort to assess and monitor the quality and effectiveness of laboratory testing systems which support public health objectives of tuberculosis treatment programs, the CDC Model Performance Evaluation Program (MPEP) was established to analyze the performance and practices of all known clinical and public health laboratories in the United States that perform drug susceptibility testing of isolates belonging to the Mycobacterium tuberculosis complex (MTBC). Adequate TB control depends on rapid isolation and identification of the etiologic agent, M. tuberculosis, and confirmation of the appropriate therapeutic regimen by anti-tuberculosis drug susceptibility testing. Respondents consist of staff at domestic laboratories that perform drug susceptibility testing on isolates of M. tuberculosis. Information collected will be used to evaluate and improve competency of staff and ensure the quality of test procedures being performed on clinical specimens.

US Code: 3 USC 301 Name of Law: General Powers and Duties of Public Health Service: Research and Investigations in General
  
None

Not associated with rulemaking

  78 FR 4148 01/18/2013
78 FR 22552 04/16/2013
No

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 558 558 0 0 0 0
Annual Time Burden (Hours) 156 156 0 0 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No

$65,560
Yes Part B of Supporting Statement
Yes
No
No
No
Uncollected
Tony Richardson 404 639-4965 lmr7@cdc.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
11/12/2013


© 2024 OMB.report | Privacy Policy